Leading drug makers posted moderate growth in net profits for the fiscal year (FY) 2020-2021 compared to previous FY because of various reasons including rise in sales.
The companies saw growth up to 47 per cent in net profits for the outgoing FY from that of previous FY.
Of the companies, Beximco Pharmaceuticals bagged the highest growth of 47 per cent in FY 2020-21 from previous FY.
The company has reported its EPS (earnings per share) of Tk 11.08 for FY 2020-21 as against Tk 7.54 reported for FY 2019-20.
For the FY 2020-21, Beximco Pharmaceuticals reported a net profit of over Tk 4.94 billion against Tk 3.36 billion reported for the previous FY.
The company's board of directors has recommended a 35 per cent cash dividend for the FY 2020-21 against 15 per cent cash and 10 per cent stock dividend for previous FY.
Renata has reported its consolidated EPS of Tk 51.94 for the FY 2020-21, up 26.15 per cent from the EPS of Tk 41.17 for FY 2019-20.
The company's board of directors has recommended 145 per cent cash and 10 per cent stock dividends for the year ended on June 30, 2021.
The Ibn Sina Pharmaceuticals Industry has reported consolidated EPS of Tk. 15.66 for the year ended on June 30, 2021 against Tk. 12.56 reported for the same period of the previous year.
In the outgoing FY, the company's net profit rose 24.68 per cent compared to previous FY.
The company's board of directors has recommended 47 per cent cash dividend for the year ended on June 30, 2021.
Square Pharmaceuticals reported its EPS of Tk 16.63 for the FY 2020-21 against Tk 14.62 for the same period of the previous FY.
In the outgoing FY, the company saw 13.74 per cent growth in EPS compared to previous FY.
In a disclosure, the company said its growth in core business i.e. sales of pharmaceutical products has positively affected the EPS for the current year.
"Proficient usage of raw materials and optimised utilisation of manufacturing overhead while maintaining stringent health and safety measurements to prevent Covid-19 has helped us maintaining a good cost of goods sold for the year," the company said.
The company's board of directors has recommended a 60 per cent cash dividend for the year ended on June 30, 2021.
It disbursed 47 per cent cash and 5.0 per cent stock dividend in previous FY 2019-19.
The EPS of ACME Laboratories rose 8.32 per cent to Tk. 7.42 for the FY 2020-21 from Tk. 6.85 for previous FY.
The company's board of directors has recommended 25 per cent cash dividend for the year ended on June 30, 2021.
SILVA Pharmaceuticals has reported EPS of Tk. 0.88 for the year ended on June 30, 2021 as against Tk. 0.87 for the same period of the previous year.
The company's EPS advanced 1.14 per cent for the FY 2020-21from that of previous FY.
Of the companies whose net profit declined, the EPS of Indo-Bangla Pharmaceuticals went down by 14 per cent to close at Tk 1.18 for the FY 2020-21 from Tk 1.37 reported for the previous FY.
Many drug makers are yet to publish their financial statements for the year ended on June 30, 2021.
mufazzal.fegmail.com
© 2024 - All Rights with The Financial Express
